GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Stock Based Compensation

ACTU (Actuate Therapeutics) Stock Based Compensation : $2.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Stock Based Compensation?

Actuate Therapeutics's Stock Based Compensation for the three months ended in Dec. 2024 was $1.19 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was $2.00 Mil.


Actuate Therapeutics Stock Based Compensation Historical Data

The historical data trend for Actuate Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Stock Based Compensation Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Stock Based Compensation
0.65 0.42 2.00

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only 0.12 0.15 0.09 0.57 1.19

Actuate Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.00 Mil.


Actuate Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Actuate Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.